Chemotherapeutic Myokines from Contracting Skeletal Muscle and Their Effects on Breast Cancer by Davis, Amanda Renee
CHEMOTHERAPEUTIC MYOKINES FROM CONTRACTING SKELETAL 
MUSCLE AND THEIR EFFECTS ON BREAST CANCER 
 
A Dissertation 
by 
AMANDA RENEE DAVIS  
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,  James D. Fluckey  
Committee Members, Steven E. Riechman 
 John M. Lawler 
 Weston W. Porter 
Head of Department, Richard B. Kreider 
 
May 2017 
 
Major Subject: Kinesiology 
 
Copyright 2017 Amanda Renee Davis
 ii 
 
 
ABSTRACT 
  
Exercise has been shown to elicit beneficial effects in both the treatment and 
prevention of cancer, yet the biology potentiating the effects remains ambiguous. The 
hypothesis for this dissertation was that effluent perfusion medium from contracting 
skeletal muscle contained factor(s) responsible for the cytotoxic effects of exercise on 
breast cancer cells. To date, no studies exist designed to eliminate confounding humoral 
factors, in vivo, while still mimicking the effects of exercise via neural activation of the 
muscle. We addressed this issue by stimulating the muscle via neural activation using an 
in situ, hemicorpus hind limb perfusion preparation. To assess the acute impact of 
muscle contractions on breast cancer, we first collected medium perfused through 
quiescent (Non-STM) muscle, subsequently followed by medium collected from 
contracting (STM) muscle of rats.  To determine if the acute impact of contracting 
muscle is altered by prior muscle conditioning, we compared acute responses of muscle 
contraction on breast cancer from control (Non-EX) vs. treadmill exercised (EX; 5d/w; 
1h/d for 5w) rats. We also assessed the impact of a common carrier of molecules in the 
bloodstream, by preparing the perfusion medium with or without albumin, using Dextran 
as the oncotic agent for these experiments.  
The results of these studies confirmed our hypothesis that effluent media 
prepared with albumin from contracting muscle (STM) displayed an average percent 
reduction of MCF7 cell counts by 20% (p = 0.014) compared to Non-STM, and prior 
exercise conditioning did not alter this effect (STM = EX; p=0.563). Albumin-prepared 
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medium yielded similar cell counts as cell controls.  Interestingly, the chemotherapeutic 
effect was not present using medium prepared with Dextran, with or without STM, 
suggesting albumin as a carrier molecule that is necessary for chemotherapeutic activity. 
To our knowledge, our results support a decrease in MCF7 cell proliferation from a 
factor secreted from contracting skeletal muscle, independent of humoral contributors; 
and are the first to demonstrate that the magnitude of the chemotherapeutic effect of 
contracting skeletal muscle is not altered by prior exercise training, suggesting that 
muscle contractions are the key contributors to this anticancer effect and not a result of a 
training adaptation.   
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NOMENCLATURE 
 
HHLP Hemicorpus Hind Limb Perfusion 
Non-STM Quiescent Muscle/Not Electrically Stimulated 
STM Electrical Stimulation 
EX Exercised (via Treadmill)  
Non-EX Non-Exercised Control/Normal Cage Ambulation 
CC Cell Culture Control 
HR± Hormone Receptor 
HER2 Human Growth Factor-neu Receptor 
MCF7 Human Breast Cancer Cell Line (Michigan Cancer Foundation)  
 
MDA-MB-231 Human Breast Cancer Cell Line (MD Anderson) 
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CHAPTER I 
 
 INTRODUCTION: BACKGROUND AND SIGNIFICANCE 
 
Breast Cancer 
According to the World Health Organization, breast cancer is the most common 
type of cancer that kills women world-wide (for an entire overview, see the full World 
Cancer Report (108)). In our nation, out of all new cases of cancer diagnosed in females, 
14% is attributed to breast cancer, which accounts for more than 235,000 women (84). 
While the mortality rates of females diagnosed with this disease have steadily decreased 
by approximately 1.9% each year from 2003-2012, it is still estimated that over 40,000 
women will die of breast cancer by the end of 2016.  
Breast cancer develops when a normal cell found in breast tissue transforms into 
a neoplastic (tumor) cell, due to an interaction between a person’s genetic factors and 
various environmental factors. In short, this transformation is a multistage process of 
abnormal gene expression that leads to dysregulation in the balance between cell 
proliferation and cell death. The increased cell growth and decreased cell death leads to 
the expansion of tumor tissue. A benign, or localized, tumor becomes malignant with 
further alterations in gene expression that eventually lead to decreased attachment from 
and invasion into surrounding tissue, blood vessels or the lymphatic system: a process 
known as metastasis.   
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Breast Cancer Subtypes 
The process of mammary tumorigenesis is further complicated as there are 
different cell types found in breast tissue (e.g. adipose, lobes, lobules, ducts, connective 
tissue, lymph, etc.), and one tumor may exhibit varying genotypic and phenotypic 
characteristics depending on the original neoplastic cell (24, 95). Even further, the 
stromal microenvironment can also strongly influence this process (80, 120). This 
etiological heterogeneity of breast cancer largely affects the clinical heterogeneity (e.g. 
prognostic characteristics, diagnostic detectability, and response to treatment), which 
elicited focused research on the characterization of breast cancer subtypes.  
There are five widely accepted molecular subtypes of breast cancer (31, 95, 104, 
105) generally characterized by the expression of basal (myoepithelial) or epithelial cell 
markers (32, 47, 86), hormone receptor (HR±) status (35), and expression of human 
growth factor-neu receptor (HER2±) (103). These subtypes are described as Luminal A 
(HR+/HER2-), Luminal B (HR+/HER2+), HER2 over-expression (HR-/HER2+), Basal-
like (HR-/HER2-) and Normal-like (HR+/HER2-). While Normal-like mammary tumors 
share the same HR status as the Luminal A subtype, they express more genes 
characteristic of basal and adipose cells (95). 
The Luminal A subtype represents 72.6% of all cases (67), being the most 
commonly diagnosed breast cancer. In the present study, we chose the MCF7 cell to 
study breast cancer due to its characterization as a Luminal A type (54, 89). The second 
most prevalent subtype was found to be the Basal-like, also known as triple-negative 
breast cancer, accounting for approximately 13% of all breast cancers (67). The MDA-
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MB-231 cell line resembles a Basal-like breast cancer (54, 89) and was chosen to 
represent the opposite end of the spectrum of breast cancer subtypes in terms of 
metastatic potential and decreased prognosis.  
Cost 
The persistent research to understand the cell biology of breast cancer in 
conjunction with the application to the clinical realm has resulted in many new, yet 
unfortunately costly, clinical therapies that are potentially inaccessible for many 
diagnosed with breast cancer. The cost of treating breast cancer continues to rise from an 
estimated national cost of $16.5 billion in 2010, to a 32% increase by 2020 (78). Despite 
the recent advances in the availability of quality health care and health insurance to help 
with the direct medical costs of treatment, the financial feasibility of all the indirect costs 
of treatment (e.g., childcare, housing, loss of productivity or income) makes many of the 
current treatment modalities nearly impossible for many women diagnosed with breast 
cancer to participate. Further, that does not account for over half of breast cancer 
mortalities that occur in low- and middle-income countries due to lack of diagnostic and 
treatment options (4). This highlights the need for more cost effective treatment 
modalities as well as the importance of education and further research on prevention and 
ways to decrease one’s risk of developing breast cancer as a long-term cost-effective 
way to control this disease.   
Risk Factors 
There are many known risk factors associated with breast cancer, some of which 
are modifiable and some which are not. Just a few of the non-modifiable risk factors for 
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breast cancer include aging, age at menarche or menopause, and family history, 
including heritable risk factors (BRCA1/2, PTEN, and CHEK2 among others). (For a 
more extensive list of risk factors and correlating studies, see website sponsored by 
Susan G. Komen (1)). Still other risk factors that are not necessarily modifiable include 
the age of parity and ability to/duration of breastfeeding. Fortunately, there are some risk 
factors that an individual can take action against and move towards the prevention of 
breast cancer.  Some of the modifiable risk factors include dietary factors, smoking, 
some environmental factors, and most importantly for the remaining discussion in this 
dissertation, physical activity levels.  
The Crossroads of Breast Cancer and Exercise 
Physical inactivity has been implicated for increased rates of many non-
communicable diseases, and is specifically targeted to be the cause of 10% of breast 
cancer cases worldwide (71).  The inverse relationship between physical activity and 
breast cancer risk in humans has been recognized since the 1980s (44), nevertheless, 
more recent estimates of relative risk reductions range from 20-80% in post-menopausal 
women and 15-30% among pre-menopausal women (42, 43, 81). One of the most 
commonly cited reviews by Lynch et al. revealed a 25% risk reduction of breast cancer 
across 73 studies done worldwide amongst physically active women as compared to the 
least active women (76). A more recent review by Wu et al. detailed a linear dose-
response relationship between the intensity of physical activity and breast cancer risk 
using a meta-analysis of the literature (126). Light intensity physical activity has 
contradicting results as to whether or not it reduces breast cancer risk (42, 66, 76, 117).  
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Breast cancer survivors who engage in regular physical activity provide the 
strongest evidence for an association between physical activity and cancer outcomes 
when compared with survivors of any other type of cancer (12). Nearly all breast cancer 
studies observed in the review by Ballard-Barbash et al. (12), reported a reduction in 
breast cancer-specific mortality as well as all-cause mortality. In both breast cancer 
patients undergoing adjuvant therapy and breast cancer survivors, physical activity has 
been shown to increase perceived measures of “quality of life”, mood, and/or in overall 
health (10, 21, 40). Further, physical activity is implicated as a method to counteract the 
negative side effects of chemotherapy, such as reduced physical fitness, depression, 
anxiety, pain, nausea, negative changes in body composition, increased fatigue, etc. (3, 
28, 29, 36, 62, 119).  
Indirect Mechanisms of Exercise on Breast Cancer 
There are several postulated mechanisms of how physical activity affects breast 
carcinogenesis, and subsequently, many reviews have been written on this topic (41, 76, 
87, 88, 96, 122). Primary dogma of the benefits of exercise on breast cancer prevention 
and progression postulates the effects are indirect and are attributed mainly via altering 
the sex hormones, breast development, insulin resistance, energy balance, body 
composition, adipokines and inflammatory markers. This presumption is based on 
observations that alterations to these important biological systems under chronic 
sedentary conditions, particularly with obesity, have been linked to increases in breast 
cancer risk (6, 9, 13, 17, 30, 38, 97, 102, 121). More specific prospective mechanisms of 
exercise protection against cancer include strengthened immune function (5, 46, 74), 
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enhanced antioxidant and oxidative damage repair capacity (85), DNA repair capacity 
and epigenetic alterations to DNA (22, 92), and Vitamin D exposure (110, 118). 
Direct Mechanisms of Exercise on Breast Cancer 
Many of these mechanisms have been further explored with rodent models of 
chemically induced or injected tumors. Extensive work in this field led Thompson et al. 
(114) to suggest a more direct paradigm of physical activity on the attenuation of tumor 
initiation and progression. The first two candidate mechanisms proposed stemmed from 
the effects of exercise on growth factors and hormones, and how the decrease in energy 
may be attenuating anabolic signaling pathways. However, after further exploring 
circulating biomarkers, cellular processes and molecular mechanisms within their model 
of chemically-induced tumors in rats (130), their results did not fully explain the 
attenuated levels of anabolic activity being directly related to energy status in their 
model. They then suggested a 3rd potential mechanism that a cytokine may be released 
through contracting skeletal muscle potentiating these effects. The experiments that 
follow in this dissertation gives credence to Thompson’s hypothesis in that the 
chemotherapeutic effect of exercise may be modulated through a cytokine, independent 
of hormones, since our methodology eradicates the influence of endocrine organs 
(namely the pancreas, liver and reproductive organs) that may be secreting hormones 
into the blood stream during exercise.  
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Additional Considerations  
Finally, with many of these proposed mechanisms, it is important to bear in mind 
the etiological heterogeneity of breast cancer and that it is likely that multiple pathways 
are involved in the carcinogenic process, and may act synergistically under conditions of 
cancer growth. Thus, the slowing of cancer growth may result from multiple 
mechanisms impacted by the improved physical conditioning following exercise 
training. It may be important to note that different types of physical activity or dose may 
preferentially elicit certain mechanisms over others. Still even further, various subgroups 
of women may differentially respond to physical activity (25, 75).  
Despite the accumulating research done on the effects of physical activity and 
breast cancer, many of the proposed mechanisms of physical activity are either indirectly 
mediated through decreased body weight, or are attributed to other whole-body 
adaptations and benefits of physical activity. Granted, while some of these postulated 
mechanisms are more fundamental in nature than others, the present series of studies are 
designed to focus on the direct impact of contracting skeletal muscle on breast cancer 
using a specific methodology to limit contributions of humoral factors, genetic factors 
and immune function.  
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Myokines: The Mechanism of Exercise  
 To support the notion that contracting muscle directly affects carcinogenesis, 
skeletal muscle has been identified as a functioning endocrine organ in the secretion of 
hundreds of various cytokines, peptides and proteoglycans, termed myokines, where 
variable secretion and expression are likely regulated by contractile activity (100, 109, 
128). Myokines exert specific autocrine, paracrine or hormone-like effects, and have 
been proven to effect signaling pathways involved in muscle homeostasis and 
inflammation (16), endothelial cell function (93) and pancreatic β-cell function (15) to 
name but a few. Thus, research targeted on the secretion and action of myokines during 
muscle contractions and their potential effects on the carcinogenic process form a 
convincing argument for a direct mechanism as to why exercise may be beneficial in 
cancer prevention and treatment (8, 45, 82, 99).  
Two studies, done over the span of 50 years, (52, 82), demonstrated a factor 
circulating in the blood of fatigued animals has chemotherapeutic effects on tumor-
bearing rats. The original paper published in 1962 by Hoffman et al. (52) revealed a two-
part study to describe the effects of exercise on tumor growth. First, they injected 
Walker 256 tumors into two groups of Wistar rats and measured tumor growth. The 
tumors in the control group consistently exceeded the size of the tumors in the group 
subjected to vigorous exercise, with some tumors showing complete regression. To 
better explain the source of this chemotherapeutic factor, the second study also injected 
rats with a tumor, but instead of using an in vivo exercise protocol, the experimental 
group was given an injection of a “fatigue-substance” prepared from a water bath of 
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electrically stimulated rectus femoris muscles. Once again, the tumor weight of the 
control group exceeded that of the animals given injections.  
A more recent study from the same group by Munoz et al. (82) prepared the 
same “fatigue substance” as previously described and further evaluated the substance 
with a cell proliferation assay and a rat cytokine antibody array. Their results indicated 
decreased cell proliferation of MCF7 cells upon treatment with “fatigue substance” as 
compared to the unstimulated muscle bath preparation. Furthermore, they identified six 
cytokines that were differentially expressed in the substance from stimulated versus 
unstimulated muscles.   
In addition to those studies, a study by Hojman et al. (53) collected serum from 
exercised mice and media from stimulated murine C2C12 muscle cells and saw decreased 
MCF7 cell proliferation when compared to serum from non-exercised mice and media 
from non-stimulated C2C12 cells, respectively (53). They also used PCR array analysis to 
identify oncostatin M (OSM) as a possible candidate of mediating the anti-proliferative 
effect on breast cancer cells. An analogous study in humans collected serum from 10 
adult males before and after 60 minutes of exercise on a bicycle, and observed attenuated 
growth of a prostate cancer cell line (LNCaP) after exposure to exercised serum (99). 
This same study demonstrated delayed tumor formation and growth after pre-incubation 
of LNCaP cells with exercise serum before injection into SCID mice compared to pre-
incubation with rest serum. Even though they attribute the mechanism of exercise to be 
mediating endogenous hormone levels, their model does not disprove the notion that 
myokines secreted from contracting skeletal muscle may be attenuate malignant growth.  
 10 
 
 
Together, these studies indicate that there may be a direct mechanism of exercise 
to reduce/slow cancer. The present studies resulting in this dissertation sought to expand 
on that work by using a methodological approach that directly assessed the cancer 
therapeutic effect of factor(s) arising directly from intact skeletal muscle, without 
confounding humoral factors in serum from exercised animals.  
Albumin: Implications for Breast Cancer Treatment 
 Albumin is the most abundant blood protein in mammals with a concentration in 
humans of 35-50 mg mL-1, which represents about 50-70% of plasma proteins. Not only 
is albumin the most abundant blood protein, it is also the most abundant protein in the 
body with approximately 1/2 kg being distributed among the blood circulation, the 
lymphatic system and the extracellular and intracellular compartments. Albumin is the 
main protein responsible for creating oncotic pressure in the blood and it is also the most 
versatile carrier protein for an array of molecules, such as metabolites, ions, amino acids, 
and fatty acids to name just a few. 
 As one of the plasma proteins, albumin is a major source of nitrogen and energy, 
as an amino acid/nutrient source, in the blood in which cells are able to utilize after 
endocytosis and lysosomal degradation. Tumor cells are characterized by high metabolic 
activity and thus, demand resources to meet their increased cellular growth and 
proliferation. Albumin has been proven to be preferentially sequestered by tumor cells at 
a rate of about 4 times more than the kidneys and about 3 times more than the liver 
(127). Because of this and its abundance and versatility as a transport protein in the 
blood circulation, albumin has been targeted as a drug carrier to improve the 
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pharmacokinetic profile of many therapeutic agents as well as a drug delivery system to 
the pathogenic site (37, 68, 69). Considering the wide-reaching implications of albumin 
in chemotherapeutic drug therapy and its necessity for methodologies utilized by this 
dissertation, we assessed the role of albumin on the chemotherapeutic impact of 
contracting skeletal muscle. For further information discussing the developments of the 
four main technologies using albumin in drug delivery within preclinical and clinical 
phases, see full review by Elsadek and Kratz (37).  
Significance, Innovation and Specific Aims 
Significance 
Since breast cancer is a major cause of morbidity, mortality and health care costs, 
it has been the focus of many research initiatives. One of the overarching challenges put 
forth by the United States Department of Defense, among others, is to “revolutionize 
treatment regimens by replacing them [drugs that have life-threatening toxicities] with 
ones that are more effective and less toxic (2).” My research focused on this challenge 
by applying the use of exercise as a safe, effective, non-toxic intervention to transform 
the current clinical methodologies for treating breast cancer.  
The background discussion above reflects the research done in the fields of 
exercise physiology and cancer biology. Each have made vast strides in the 
understanding of cell signaling and processes, as well as implementing new knowledge 
to achieve optimal health and treatment methodologies.  The contribution of this 
dissertation is significant because of the integration of these two fields, cancer biology 
and exercise physiology, with mutually beneficial outcomes of how exercise affects the 
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signaling pathways implicated in cancer initiation and progression. From the 
perspective of exercise physiology, the consequential acquisition of knowledge 
pertaining to the mechanism by which exercise affects signaling pathways in neoplastic 
cells will lead to confidence in the clinical application of exercise within the “cancer 
population”.   
The results from this dissertation will also strengthen our understanding of the 
therapeutic benefits of exercise and potentially identify contraindications for patients 
with certain types of cancers. The effect of habitual conditioning on the secretion of a 
“chemotherapeutic exercise-factor” will prove to be a strong impetus for a more active 
lifestyle. In cancer biology, this dissertation will lead to further discussion on the 
signaling pathways in cancer cells that can be targeted for treatment. Finally, in the 
clinical realm, the use of exercise is an inexpensive treatment option that is easily 
accessible and one that is without the toxic side effects of radiation and chemotherapy.   
Innovation 
To date, studies have not been performed to control for the potentially 
confounding humoral factors in vivo, while still mimicking the effects of exercise via 
neural activation of the muscle. In the Hojman study previously mentioned (53), serum 
was collected in an in vivo model where there may be other systemic factors involved, 
and thus, confounding the mechanism by which exercise exerts its effects.  In the 
opposite extreme, they include an in vitro model where myotubes were grown in cell 
culture.  The studies done by Hoffman (1961) and Munoz (2013), utilized an ex vivo 
model where the skeletal muscle has been excised and maintained in a saline bath (52, 
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82). In both the in vitro and ex vivo approaches, the skeletal muscles/cells were 
contracted and maintained in a non-physiological environment. The innovation of this 
dissertation was the ability to identify Arterial-Venous differences in non-stimulated and 
stimulated perfusate from the same animal while maintaining and controlling the 
physiological environment using an in situ model. To accomplish this, we employed the 
Hemicorpus Hind limb Perfusion (HHLP) technique to isolate the factor(s) where the 
event occurs in the desired, optimal location, which in this case is from in-tact, neural 
activated, contracting skeletal muscle. As described further in the Methodology section, 
the blood supply to the renal, reproductive and digestive systems are ligated to prevent 
confounding humoral factors from entering into the perfusate. 
The preliminary work that guided the proposal of this dissertation was done to 
reproduce and verify similar results to work done earlier in collaborative efforts with 
Kim Westerlind (64). We determined four days of treatment was the optimal length of 
time to run a cell proliferation experiment on MCF7 cells exposed to three different 
percentages (5%, 10%, and 20%) of perfusate from HHLP (34). The results in Figure 1 
verified our in situ model to be effective in releasing chemotherapeutic factor(s) from 
electrically-stimulated skeletal muscle by the decrease in MCF7 cell growth. In the 10% 
and 20% treatment group, the MCF7 cells exposed to skeletal muscle perfusate from 
electrically stimulated skeletal muscle (STM) had significantly lower cell counts than 
perfusate from quiescent skeletal muscle (Non-STM), p=0.048 and p=0.0025 
respectively. 
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Figure 1. MCF7 Cell Counts After Treatment with Various Percentages of Skeletal 
Muscle Perfusate. MCF7 cells were treated for 5 days with skeletal muscle perfusate 
from a hemicorpus hind limb perfusion preparation. Perfusate from quiescent skeletal 
muscle (Non-STM) and from electrically stimulated skeletal muscle (STM) were added 
to standard cell culture media at various percentages to identify optimal percentage for 
future experiments. Control consisted of standard cell culture media without the addition 
of skeletal muscle perfusate. * Denotes statistical significance at p < 0.05. 
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Specific Aims 
The objective of this dissertation was to characterize the factor(s) released during 
exercise that have direct, chemotherapeutic effects on breast cancer cells. This objective 
expanded upon our preliminary work and work done in collaboration with Kim 
Westerlind (64). The central hypothesis for this proposal was that a single myokine is 
responsible for the cytotoxic effects of exercise on breast cancer cells. Understanding 
how the secretion of this myokine was associated with activity levels, ranging from 
normal cage ambulation to moderate, habitual exercise, has wide-reaching ramifications 
for differences in lifestyles on cancer risk and prognosis.  
The following Specific Aims guided us in accomplishing the objective and in 
testing the hypothesis of this dissertation;  
1. Identify changes in cellular proliferation of breast cancer cells after treatment 
with muscle perfusate collected from skeletal muscle during an acute bout of 
simulated exercise. Additionally, determine whether prior exercise had an effect on 
the chemotherapeutic response.  
The hypothesis was that a myokine released from contracting skeletal muscle would 
have a cytotoxic effect on breast cancer cells. In addition, we hypothesized that prior 
exercise conditioning would accentuate the cytotoxic effect.  
2. Determine the role of albumin on the chemotherapeutic factor within the 
perfusate.  
The hypothesis for this aim was that the chemotherapeutic factor required 
albumin as a carrier protein in the perfusate/blood.  
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CHAPTER II 
 METHODOLOGIES 
 
To achieve the specific aims of this dissertation, the following methodologies 
were used.  
Hemicorpus Hind Limb Perfusion (HHLP) 
Animals 
 Female Wistar rats 8-12 weeks old, weighing 275-375g were used. All animals 
were housed two per cage under a standard 12-hour photoperiod. The animals were 
provided with normal Rat Chow and water ad libitum until the administration of 
anesthesia. All procedures were approved by the Animal Care and Use Committee of 
Texas A&M University.   
Reagents and Perfusion Medium  
A modified Krebs-Henseleit bicarbonate buffer was used as the perfusion 
medium. Krebs-Henseleit bicarbonate saline (70) was prepared by combining 2.1g 
NAHCO3 dissolved in 250mL of deionized water that had been gassed for 30 minutes 
with 95% O2:5% CO2, with a working buffer solution containing 118.5 mM NaCl, 4.7 
mM KCl, 3.4 mM CaCI2.2 H2O, 1.2 mM KH2PO4, and 1.2 mM MgSO4. 7 H2O per liter. 
Bovine serum albumin (Fraction V; Amresco, Solon, OH) was dissolved in sterile-
filtered Krebs-Henseleit bicarbonate buffer to obtain 3.5g/100mL. Dextrose was added 
to obtain 90-100mg%, and the solution was refrigerated at 4°C for no longer than 48 
hours before the perfusion procedure. We chose an erythrocyte-free preparation to 
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simplify perfusate preparation and avoid potential confounding effects of erythrocyte 
metabolism (14, 79, 101). To further study the role of albumin in the perfusate, the same 
perfusion medium described above was prepared with Dextran (Clinical Grade; MP 
Biomedicals, LLC, Solon, OH) in place of the bovine serum albumin.  
Surgical Preparation and Perfusion of the Hind Limbs  
An initial intraperitoneal injection of 0.75mg Ketamine HCl, was administered to 
anesthetize the rat; additional dosing was administered as needed. Rear foot reflexes 
were tested to confirm anesthesia before abdominal midline and transverse incisions 
were performed to expose the abdominal cavity. Evisceration of the digestive and 
reproductive organs preceded ligation of major arteries branching from the descending 
aorta to prevent confounding humoral factors from entering the perfusate. This was 
achieved by first placing a ligature around the base of the uterus and ovaries, along with 
the neck of the bladder, and excising those organs along with contiguous adipose tissue. 
Next, two ligatures were tied in the descending colon and incised between the ligatures. 
Another ligature was placed anterior the stomach and the digestive organs were excised.  
Two sets of loose ligatures were placed around the descending aorta and the inferior 
vena cava, one just posterior to the origin of the renal arteries and the other just posterior 
to the origin of the iliolumbar arteries. The most anterior ligature around the descending 
aorta was tied and an 18mm gauge FEP polymer cannula (Jelco 4054; Smiths Medical 
International Ltd., Southington, CT, manufactured in the UK) was immediately inserted 
and tied into place with both ligatures. A transparent vinyl tube connected the cannula to 
a Watson-Marlow peristaltic pump (Wilmington, MA, manufactured in the UK), which 
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was calibrated and set to produce a flowrate of 8-12 ml/min (98), and was increased 
upon the start of contractions up to 20 ml/min to maintain adequate pressure and flow. 
The perfusion medium was warmed to 37°C (Warner Instruments Corp., Hamdon, CT, 
USA) and gassed with 95% O2:5% CO2.  Perfusion was immediately continued with 
Krebs-Henseleit bicarbonate buffer after the aortic cannula was in place to make sure 
cannulation was successful, then was briefly paused to cannulate the inferior vena cava 
in the same manner of the aorta. A terminal cardiac stick with 0.1mg Ketamine HCl 
followed the cannulation of the abdominal aorta and vena cava. The perfusate flowed 
through the hind limbs, out the cannulated vena cava and was collected into pre-labeled 
vials. A brief 3-5 minute wash out period allowed for the majority of red blood cells and 
serum to flush out of the hind limbs. The efferent perfusate was then collected for 5-10 
minutes from quiescent hind limbs and identified as Non-Stimulated (Non-STM) 
perfusate.  
Electrical Stimulation 
For muscle contraction, the sciatic nerve in its gluteal course, distal to the hip 
joint was carefully exposed and clamped with a low voltage S48 Electrical Stimulator 
(Astro Med Inc., Warwick, RI, USA). The electrical stimulation protocol from Hespel et 
al. (50) was followed with a few adjustments. The hind limb was electrically stimulated 
with trains of 100ms at 100Hz, with each train lasting for 10ms. Voltage was adjusted 
between 4-15V based on contraction strength to ensure constant muscle contractions 
until fatigue. The trains were delivered at a rate of 60/min for up to 35 minutes. 
Perfusate was collected during muscle contractions in one minute intervals into pre-
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labeled vials. Once the muscle reached fatigue and no longer displayed visible 
contractions, the electrical current and collection of perfusate was discontinued. Unless 
otherwise specified, for the majority of experiments, the perfusate from the last 5-7 
minutes of muscle contraction were pooled and identified as the Stimulated (STM) 
group. This methodology is similar to rat hemicorpus perfusion models used in the study 
of muscle metabolism (50, 59-61, 98). A schematic of the protocol is shown in  
Figure 2.  
All perfusate was kept on ice during collection and centrifuged at 2,500 rpm for 
25 minutes in 4°F to spin down any debris and erythrocytes. The supernatant was 
aspirated and pooled according to predetermined groups and immediately frozen to -
80°C. A sample of the Krebs-Henseleit buffer solution used for each experiment was 
(labeled “K”) and preserved at -80°C as a control. 
Perfusate samples were thawed and pipetted into pre-labeled 1mL aliquots, and 
maintained at -80°C until cell culture experiments were prepared. 
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Figure 2. Schematic of Hemicorpus Hind limb Perfusion Protocol. Modified Krebs-Henseleit buffer was pumped through the 
cannulated abdominal aorta. Efferent flow through the cannulated vena cava was collected in conical tubes kept on ice. 
Perfusate was then spun down to remove RBC or debris. Supernatant was collected and frozen to -80°C for storage. Once 
perfusate was collected from quiescent hind limbs, electrical stimulation was applied to the same animal’s sciatic nerve and 
perfusate was collected using the identical protocol as previously described. 
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Exercise Protocol 
Moderate-intensity exercise was chosen for this study as it has consistently 
shown to be beneficial in improving and maintaining health. In fact, the American 
College of Sports Medicine and the American Heart Association jointly recommend 
healthy adults to achieve moderate-intensity physical activity for at least 30 minutes per 
day, 5 days a week or vigorous-intensity physical activity for 20 minutes on 3 days each 
week (48). In regards to the effects of exercise on breast cancer in rodents, Thompson et 
al. (116) conducted a study targeting exercise intensity on the effects of chemically 
induced mammary carcinogenesis. They suggest a threshold of 35% maximal exercise 
intensity to be reached before any beneficial effects of exercise would be realized. In 
addition, they propose a linear relationship between exercise intensity and the beneficial, 
protective effects of reduced cancer induction, up to 75% maximal exercise intensity 
(116). Another study by Westerlind et al. (124) reported moderate-intensity exercise to 
decrease tumor size and growth rate as well as increase tumor latency in adolescent rats. 
Therefore, the conditioning protocol that follows was chosen to elicit an estimated 
moderate intensity of 50-75% VO2max, based on work by others (18, 23, 49, 51, 57, 94).  
Our exercise protocol utilized a motorized rodent treadmill, similar to one 
described by Kimeldorf (65) and further modified by Holloszy (55). Briefly, the 
treadmill was comprised of a plastic box, partitioned into 20 lanes (2 lanes deep X 10 
lanes across) suspended over a wide, continuous belt cycling on metal rollers. The lanes 
were approximately 10cm by 50cm, allowing each rat a restricted area to run. An air gun 
was used to enforce compliance to the exercise protocol; after the first few days of 
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exercise, use of the air gun was seldom needed. Rats were exercised during the first hour 
of the dark phase within the light-dark cycle each of the 5 days.   
 After familiarization to the treadmill and belt movement, 8 rats were assigned to 
the Exercise (EX) group and 4 were assigned as age and weight matched controls (Non-
EX). Forty-eight hours after the last familiarization period, rats in the EX group 
completed a 5-week exercise program consisting of 5 bouts per week. Exercise duration 
was 60 min/day, while the speed and incline were adjusted as detailed in Table 1. A 5-10 
minute warm-up and a 5 minute cool-down period was included in the 60-minute 
exercise session. The treadmill was initially fixed with no incline, and speed was 
gradually increased the first three weeks to an average top speed of 20.5 m/min. Once 
the treadmill was raised to 15% incline at the beginning of Week 4, speed was reduced 
to maintain a comparable increase in workload. Final top speed with the 15% incline was 
an average of 15.7 m/min for the last two weeks of exercise. A technical difficulty with 
one rat on Day 2 in Week 2 prevented us from going the entire 60 minutes.  
Rats were inspected for any injuries and none were noted. The rats were also 
weighed after each exercise session; weights were recorded in a laboratory notebook. 
For transfer between the cage, rodent treadmill and scale, rats were held at the base of 
the tail. The treadmill and scale were cleaned and sanitized the end of each training 
session and were inspected for maintenance/safety concerns. At the conclusion of the 5 
week exercise program, EX rats were perfused using the rat hemicorpus perfusion 
preparation as previously described within 70-80 hours after the last exercise bout. Rats 
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assigned as age and weight matched controls (Non-EX) were perfused within 72-80 
hours of the EX group.  
 
Table 1. Treadmill Exercise Protocol 
Week 
Duration/Day 
(min) 
Average Top 
Speed/Day 
Average 
Speed/Day 
Incline 
(%) 
     
1 60 12.8 11.0 0 
2 57.6* 20.5 16.2 0 
3 60 20.3 18.4 0 
4 60 15.7 14.4 15 
5 60 15.6 14.3 15 
          
Table 1. Treadmill Exercise Protocol. Female Wistar rats (n=8) were exercised              
60 min/day, 5 days/week for 5 weeks. Average Speeds are noted in meters per minute 
m/min. * Denotes an issue with one animal that decreased the average exercise duration. 
 
 
Cell Culture 
Cell Lines 
MCF-7 and MDA-MB-231 cells were chosen as the cell lines for this 
dissertation. MCF-7 malignant breast epithelial cells, were originally taken from a 
pleural effusion of an invasive ductal carcinoma (106) and are estrogen receptor-positive 
(ER+), and progesterone receptor-positive (PR+) (58, 72). MDA-MB-231 malignant 
breast epithelial cells were also taken from a pleural effusion (19), however, these cells 
express more basal-like cell characteristics, are considered metastatic and do not have 
either the estrogen (ER-) or progesterone receptor (PR-) (58).  
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Both cell lines were obtained via courtesy from Dr. Weston Porter’s laboratory 
(Texas A&M University, Department of Veterinary Integrative Biosciences, College 
Station, TX) and grown similar to as described in Noratto et al. (91). Briefly, cells were 
cultured using Dulbecco's Modification of Eagle's Medium (DMEM) 4.5 g/L glucose, L-
glutamine, with sodium pyruvate and further supplemented with 5% (v/v) fetal bovine 
serum (FBS) and 1% (v/v) penicillin/streptomycin.  Cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. Culture media and antibiotics were 
purchased from Corning (Mediatech Inc., Manassas, VA).  
Treatment with Perfusate 
 To determine the effects of muscle contraction via electrical stimulation, breast 
cancer cells were treated with perfusates collected from quiescent and contracting 
skeletal muscle from a hemicorpus hind limb perfusion preparation. Through 
preliminary studies done by myself, (data shown in Figure 1) we ascertained a 10% (v/v) 
perfusate in DMEM to be optimal for treatment as it showed a robust response without 
the potentially confounding effects of over-dilution. Since the experiment was run in 
triplicate (3 wells for each group), a 10% (v/v) media solution was made for all three 
wells to maintain consistency of treatment. For example, 1mL of Non-STM perfusate 
was added to 9mL of DMEM media to obtain 10mL of treatment media. This solution 
was then used to culture the 3 wells of that group with 2mL each well; any remaining 
treatment media was discarded. Treatment was done in this manner to maintain 
consistency within groups; whereby, each well was exposed to the same percentage of 
perfusate.  
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Cell Proliferation 
 Cells were seeded into 6-well plates with 10,000-25,000 cells/well. Each 
experimental group had 3 wells each. The first treatment, Day 1, was administered 5-7 
hours after seeding the plates by adding 200µL/well of perfusate. For subsequent 
treatments, media was aspirated and fresh treatment media was administered to cells 
every 24 hours. For the majority of the experiments, cells were treated for 4 days and 
harvested for cell counts on Day 5.  
  To evaluate cell proliferation, viable cells were counted using an electronic 
counter (Z1 Series, Beckman Coulter, Inc.). Cells were prepped for counting by first 
aspirating the culture media from each well and rinsing with 1mL PBS. Next, 0.5mL 
trypsin was added to each well until the cells detached. To stop trypsinization and 
recover total volume, 1.5mL of fresh DMEM was added to each well. Finally, 200µL 
was taken from each well after vigorously mixing with a pipette to break up potential 
clumps of cells and then added to pre-labeled vials of 20mL isotonic solution. Cell 
counts were taken in triplicate from each of these vials.  
Impact of Muscle Contraction Perfusate on Breast Cancer Cell Proliferation  
Cell Proliferation of Breast Cancer Cell Lines After Exposure to Perfusate from an 
Acute Bout of Electrical Stimulation 
To observe differences in cellular proliferation after treatment of perfusate from 
stimulated skeletal muscle in two breast cancer cell lines, six rats were perfused using 
the HHLP protocol as described above. Perfusate was collected during muscle 
quiescence and labeled NoSTM. Once muscle contraction began, perfusate was collected 
 26 
 
 
each minute in separate vials. Minutes 1-5 were pooled and labeled Stimulation Early 
(STM-E); the last 5 minutes of contraction were labeled Stimulation Late (STM-L); if 
muscle contractions exceeded 8 minutes, then the last minutes of contraction were 
equally divided and pooled in two separate groups, Stimulation Late (STM-L) and 
Stimulation Late Late (STM-L2). As stated in the above protocol, samples were frozen 
immediately after electrical stimulation ceased and stored at -80°C for the cell culture 
component of the experiment. These perfusates were used to treat two rounds each of 
MCF7 cells and MDA-MD-231 cells as described below. 
 Fresh 5% DMEM [4.5 g/L glucose, L-glutamine, sodium pyruvate, phenol red] 
was prepared and MCF7 cells were taken out of liquid nitrogen storage at passage 15.  
Cells were grown to seed eight 6-well plates at 25,000 cells/well at passage 17. Cells 
were seeded by 10:00am and the first treatment of perfusate was administered at 4:00pm 
on Day 1 by adding 200µL of perfusate to each well (3 wells/group). On Days 2-4, 
treatment consisted of aspirating old media and refreshing the cells with a 10% (v/v) 
perfusate treatment media as described above. Perfusate from 4 rats were used for the 
cell culture component of this study. All rats had a NoSTM, STM-E and STM-L group. 
Only 2 rats had an extra STM-L2 group. 
 On Day 5, cells were harvested for cell counts and cell proliferation data was 
recorded and analyzed. (Control cells appeared 90-100% confluent and treatment groups 
appeared 80-90% confluent).  
The same cell culture experiment as described above was duplicated with 
passage 19 of MCF7 cells, seeded at 20,000 cells/well. In addition, passage 14 of an 
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MDA-MB-231 cell line seeded at 25,000 cells/ well, were treated concurrently with the 
MCF7 cells. On Day 5 when cells were to be harvested for cell counts, MCF7 cells were 
90-100% confluent and MDA 231 cells were 50-60% confluent. 
Perfusate from 5 rats were used to repeat the experiment with passage 13 of the 
MDA-MB-231 cells. Cells were seeded at 10,000 cells/well and were treated for an 
additional day.  In an attempt to maximize the potential effect, we elected to seed them 
with 10,000 cells/well as opposed to 25,000 cells/well. Also, because MDA-MB-231 
cells tended to grow more slowly, cells were harvested and counted for cell proliferation 
data on Day 6. 
Differences in Cellular Proliferation After Exposure to Perfusate from Skeletal Muscle, 
with or Without Prior Exercise, During an Acute Bout of Electrical Stimulation 
To observe potential differences in cellular proliferation after exposure to 
perfusate from skeletal muscle, with or without prior exercise conditioning, during an 
acute bout of electrical stimulation. To accomplish this objective, eight rats were 
conditioned with the Conditioning Protocol as described above. Four rats served as age 
and weight-matched controls. All rats were perfused using the HHLP protocol as 
previously described. 
Thirteen 6-well plates were seeded with MCF7 cells with 10,000 cells/well. 
Perfusates from each of the 12 rats included a Non-STM and a STM group, and the 
control plate consisted of a cell control with untreated media and a Krebs buffer group. 
The remainder of the study followed the cell proliferation protocol as previously 
described.   
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Albumin as a Required Carrier of the Chemotherapeutic Myokine(s) 
 To compare cell proliferation between Dextran and BSA perfusate, four rats were 
perfused using the HHLP protocol as described above, using BSA; a second set of four 
rats were perfused using the modified HHLP protocol as described above with Dextran 
in place of the BSA to control for osmotic pressure. Perfusates from each group were 
pooled to obtain a large volume for proteomics assessment by a collaborator. 
Approximately twenty milliliters from each group (Non-STM and STM of both Dextran 
and BSA), were divided into 5mL aliquots and stored at -80ºC. 
Four six-well plates were seeded with passage 17 of MCF7 cells. The cell 
proliferation protocol, as described above, was used for the remainder of this study.  
Statistical Analysis 
 The effect of stimulated skeletal muscle perfusate (STM) compared to non-
stimulated skeletal muscle perfusate (NonSTM) on cell proliferation are expressed as 
average percent reduction using the NonSTM cell count of each individual rat as the 
control. This was done to reduce the variability between rats and cell culture plates. 
When comparisons were made regarding fatigue and impact on cellular proliferation of 
cancer cells, a 2-way ANOVA was performed with repeated measures used across time 
and treatment.  Statistical analyses were completed using SigmaStat version 3.5. 
Significance was set at p ≤ 0.05 and all data are presented as means ± SE. 
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CHAPTER III 
 RESULTS 
 
Impact of Muscle Contraction Perfusate on Breast Cancer Cell Proliferation  
Cell Proliferation of Breast Cancer Cell Lines After Exposure to Perfusate from an 
Acute Bout of Electrical Stimulation 
To observe differences in MCF7 cellular proliferation after treatment of perfusate 
from electrically stimulated skeletal muscle, the HHLP was performed on 3 rats and 
perfusate was collected in 5 minute fractions until fatigue.  An additional group, STM-F, 
resulted from taking the fraction that represented the point of fatigue for each rat 
regardless of the time point collected. The average percent reduction from Non-STM 
control was calculated for each rat and the results for the following groups are as shown 
in Figure 4. Each fraction of electrically stimulated skeletal muscle perfusate (i.e. STM-
E, STM-L, STM-L2 and STM-F) had significantly reduced cell counts as compared to 
the quiescent skeletal muscle perfusate (Non-STM) as the control, p = 0.003, p = 0.003, 
p = 0.023, and p = 0.014, respectively (see Figure 3). A two-way ANOVA to test for 
differences among the fractions did not show any main effects, p = 0.217. 
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Figure 3. Average Percent Reduction of MCF7 Cell Proliferation After Treatment with 
Electrically Stimulated Skeletal Muscle Perfusate from Non-STM Control. MCF7 cells 
were treated for 5 days with skeletal muscle perfusate collected from quiescent muscle 
(Non-STM) and contracting skeletal muscle at different time points for n = 6 rats: the 
first 5 minutes of contraction (STM-E), minutes 6-10 (STM-L) and if contractions were 
still present, minutes 11-15 (STM-L2). The STMF fraction represents the fraction at 
which viable muscle contractions ceased. *Denotes statistical significance when cell 
counts exposed to the STM muscle perfusates were compared to cells exposed to the 
Non-STM control, p < 0.05. No differences were detected across time (p>0.05). 
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To observe differences in cellular proliferation of MDA-MB-231 breast cancer 
cells after treatment of perfusate from electrically stimulated skeletal muscle, the HHLP 
was performed on 4 rats and perfusate was collected in 5 minute fractions until fatigue.  
The STM-F fraction represents the point of fatigue for each rat regardless of the time 
point collected. The means for each group of the percent reduction of each rat compared 
to its Non-STM control are as shown in Figure 4. None of the fractions displayed a 
significant reduction in cell counts (STM-E, p = 0.883; STM-L, p = 0.347; and STM-L2  
p = 0.127); however, the STM-F fraction approached significance at p = 0.062. 
Differences in Cellular Proliferation After Exposure to Perfusate from Skeletal Muscle, 
with or without Prior Exercise, During an Acute Bout of Electrical Stimulation 
 To observe the effects of prior exercise on the effect of perfusate collected from 
contracting skeletal muscle via electrical stimulation on the cellular proliferation of 
MCF7 breast cancer cells, the HHLP was performed on rats exposed to 5 weeks of 
exercise on a treadmill and as well as age and weight matched controls. Results are 
presented in Figure 5. In both the Non-EX and EX cohorts, treatment with STM 
perfusate displayed significant average percent reductions in cell proliferation as 
compared to Non-STM control, (p = 0.003 for both cohorts). There was no difference 
between the average percent reductions in cell proliferation in response to muscle 
contractions between the control rats when compared to the exercised rats, (p = 0.895).    
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 Figure 4. Average Percent Reduction of MDA-MB-231 Cell Proliferation After 
Treatment with Electrically Stimulated Skeletal Muscle Perfusate from Non-STM 
Control. MDA-MB-231 cells were treated for 5 days with skeletal muscle perfusate 
collected from quiescent muscle (Non-STM) and contracting skeletal muscle at different 
time points for n = 4 rats: the first 5 minutes of contraction (STM-E), minutes 6-10 
(STM-L) and if contractions were still present, minutes 11-15 (STM-L2). The STM-F 
fraction represents the fraction at which viable muscle contractions ceased. There were 
no differences detected between cell counts exposed to the STM muscle perfusates as 
compared to cells exposed to the Non-STM control, p < 0.05.   
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Figure 5. Average Percent Reduction of MCF7 Cell Proliferation After Treatment with 
Electrically Stimulated Skeletal Muscle Perfusate from Non-STM Control, with and 
without Prior Treadmill Exercise. MCF7 cells were treated for 5 days with skeletal 
muscle perfusate collected from quiescent muscle (Non-STM) and contracting skeletal 
muscle via electrical stimulation from rats previously exposed to 5 weeks of exercise on 
a treadmill (EX; n = 6) and normal cage ambulation control (Non-EX; n = 8). There was 
no difference between the average percent reductions from Non-STM to STM with prior 
Exercise (EX) as compared to control (Non-EX), p = 0.895. Both had significant average 
percent reductions as compared to Non-STM control, p = 0.003.     
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Albumin as a Required Carrier of the Chemotherapeutic Myokine(s) 
To determine the role of albumin as a carrier protein in the perfusate, cell 
proliferation of MCF7 cells were compared after treatment of perfusion media prepared 
with Dextran or BSA. The STM perfusate prepared with BSA demonstrated the expected 
attenuation in cell proliferation as compared to cell Control (-26%, p = 0.013). There 
was no difference in cell proliferation of MCF7 cells after treatment of Non-STM or 
STM perfusate prepared with Dextran (p = 0.402 and p = 0.813, respectively), indicating 
the importance of albumin as a carrier of the chemotherapeutic factor(s) secreted from 
contracting skeletal muscle. See data shown in Figure 6. 
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Figure 6. Albumin as a Required Carrier of the Chemotherapeutic Myokine(s). MCF7 
cells were treated for 5 days with pooled rat skeletal muscle perfusate from n = 3 rats, 
prepared with BSA or Dextran, collected from quiescent muscle (Non-STM) and 
contracting skeletal muscle (STM) via electrical stimulation. STM perfusate prepared 
with BSA attenuated cell proliferation as compared to cell control, (p = 0.013). Perfusate 
from both Non-STM and STM was not different than control when prepared with 
Dextran, (p = 0.402 and p = 0.813). Data are expressed as means ± SE. *Denotes 
statistical significance when cell counts were compared to cell control, p < 0.05. 
 
 36 
 
 
CHAPTER IV 
DISCUSSION 
 
 The primary aim of this study was to determine if the purported benefits of 
exercise on breast cancer could be attributed to an intrinsic quality of muscle contraction 
during the locomotive process, without the confounding influence of compromised 
metabolism or humoral factors that are attributed to this benefit. To achieve this goal, we 
utilized a hemicorpus hind limb perfusion model with and without electrical stimulation 
of the sciatic nerve to collect substances secreted from contracting and quiescent skeletal 
muscle. In conjunction with this technique, we established a cell proliferation assay with 
MCF7 and MDA-MB-231 breast cancer cells to determine the chemotherapeutic effects 
of skeletal muscle perfusate. Others have implicated that muscle contraction, per se, is 
important for this chemotherapeutic action; however, to our knowledge, these data are 
the first to demonstrate the relationship between longer duration of muscle contractions 
and increasing cytotoxic effects on breast cancer cells, without the need for fatigue. 
These data are also the first to offer the notion that prior exercise training does not prove 
to have additive benefits on the release of (a) chemotherapeutic factor(s) during each 
acute bout of skeletal muscle contraction, as evidenced by similar cell MCF7 breast 
cancer cell counts after exposure to STM perfusate from Non-EX and EX.  
Impact of Muscle Contraction Perfusate on Breast Cancer Cell Proliferation  
Consistent with epidemiological and physiological studies demonstrating an 
attenuated risk and progression of breast cancer with exercise, our results support the 
 37 
 
 
concept that the very act of locomotion (i.e., contracting skeletal muscle) has a 
chemotherapeutic influence on breast cancer. Our work is consistent with the notion that 
a factor, termed myokine, is released from skeletal muscle during exercise that 
attenuates cancer proliferation (52, 53, 64, 82). To demonstrate that directly, the present 
study used perfusate from electrically stimulated hind limb skeletal muscles (STM), 
administered to MCF7 breast cancer cells suppressed cell proliferation by up to 20% 
compared to Non-STM control (p = 0.014). Surprisingly, even though the same 
experiment with a different breast cancer cell line, MDA-MB-231, displayed close to a 
25% reduction in cell proliferation in the STM-F fraction, that outcome was not 
statistically significant (p = 0.062). Early iterations of our experiments performed by 
Westerlind et al. (64) using our perfusates determined reductions of cell proliferation by 
assessing DNA damage repair and apoptosis. Those studies demonstrated that 
contracting muscle profoundly elevates apoptosis in two cell lines [+127% in MCF7 and 
+190% in MDA-MB-231s] when compared to Non-STM cells as determined by 
morphological criteria. The present study expanded on that work by noting that cell 
counts are reduced in both cell lines over 5 days of treatment with STM perfusate. 
Together, our work clearly implicates that substances arising from contracting skeletal 
muscle being carried through the vascular system remain viable and capable of 
attenuating cancerous growth.   
It is of notable mention that the benefits of exercise may not prove to be equal in 
every tumor cell type. There have been conflicting studies (27, 33, 63, 83, 107, 115) 
displaying the varied adverse responses of exercise on tumor growth. Our data clearly 
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indicate the benefits of exercise in MCF7 cells, which represents the Luminal A subtype. 
In addition, although it did not quite reach significance, exercise appeared to show a 
cytotoxic effect on the MDA-MB-231’s, a triple negative breast cancer cell type. The 
present data also support the many studies done in animals proving the beneficial effects 
of exercise on breast cancer initiation and progression (7, 11, 26, 52, 53, 64, 77, 82, 83, 
116, 123-125, 129-131). It is important to keep in mind that many signaling pathways 
are aberrant in tumorigenesis, and while one particular pathway may be aberrant in 
some, it may not be in another. This warrants the continued exploration into what 
signaling pathways are affected in cancer with exercise. 
In the literature, the specifics of intensity, frequency, and duration of exercise to 
maximize the benefit of exercise on breast cancer remain ambiguous. There was a dose-
response association observed with the protective effects of physical activity on breast 
cancer, in support of moderate activity (>4.5 MET) more than light activities (<4.5 
MET) (117). However, in a review of the exercise studies done in breast cancer 
survivors that targeted the report of findings in view of the principles of exercise 
training, the limitations in interpreting current literature as the frequency, dose and 
intensity of exercise, as well as the adherence to exercise protocols, are unclear or not 
reported (20). Further, a review of the chemically-induced breast cancer model in 
rodents discussed the differences observed in voluntary physical activity and a more 
structured form of exercise, and the need for defining laboratory studies in the context of 
the intensity and duration of exercise (111, 112). The same group also highlights the 
usefulness and importance of animal models in defining these parameters for highly-
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translatable findings in the pre-clinical field of research (113). While the current work 
was not designed to determine dose-response relationships between exercise and 
attenuation of breast cancer, our data do provide further insights on the secretion of this 
factor due to our experimental design. Our study indicates that the benefit of repetitive 
muscle contractions regarding breast cancer are observed within the first 5 minutes of 
muscle contractions (STM-E), eliciting a 7% reduction in MCF7 cell proliferation (p = 
0.003), suggesting that this myokine is already resident in the cell and capable of 
excretion within 5 minutes of repetitive contractile work. That said, it is also obvious 
that fractions collected sequentially seem to have a greater effectiveness than the 
previous fraction, as the impact of the perfusate on cancer cell lines increased with each 
fraction displaying augmented percent reductions in cell proliferation [10% reduction 
with STM-L and ~20% with STM-L2 and STM-F], suggesting that either the 
substance(s) is(are) being manufactured during the contractile process, or that the 
packaging/release of the substance(s) requires time to be maximized. These data expand 
on the work of Hoffman and Munoz (52, 82), which ascribes this chemotherapeutic 
factor to be a “fatigue substance” (named F-substance) because muscles were contracted 
to fatigue. However, the collection of skeletal muscle secretions with electrical 
stimulation occurred in a saline bath preparation that collected everything from the start 
of contractions until fatigue, so postulating that the benefit of exercise on cancer 
required fatigue was overstated. Our results are the first to clearly implicate that the 
release of a chemotherapeutic factor is indeed enhanced with the longer duration of 
muscle contractions; however, fatigue is not necessary to bring about its release. This is 
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supported by the work of Hojman et al. (53) that demonstrated attenuated MCF7 cell 
growth after exposure to exercise serum in which mice swam for 1 hour, not necessarily 
until fatigue. In addition, the study by Rundqvist et al. (99) only had their human 
subjects exercise for 1 hour (at moderate intensity of 50-65% VO2max) before collecting 
exercise serum in their study displaying diminished prostate cancer growth on cells 
treated with exercise serum.  
The intensity of exercise needed to elicit the chemotherapeutic benefits of 
exercise cannot be addressed with our data. However, the intensity of muscle 
contractions in our protocol was based off the strength of contraction needed to 
maximize glucose uptake in skeletal muscle (39) which results in a dramatic exocytosis 
of vesicles to plasma membrane surfaces in muscle to elevate glucose transporter 
content. Although the release of myokines was not the focal point for that study, we 
suspected that glut4 containing vesicles contain factors that are released into the blood 
stream during exercise, and our goal was to maximize exocytotic opportunities in the 
present model. Further work is warranted to explore the emerging mechanism for 
myokine release with exercise. And once again, our study was not designed to answer 
specific questions on a clinical prescription of exercise, but is useful in proving the 
importance of muscle contraction as the mechanism of exercise that is cytotoxic to 
cancer cells. 
 It has been long accepted that repetitive bouts of exercise over time elicit a 
training effect on the body that extend beyond the impact of a single bout. Using this 
construct of a training effect, it stands to reason that repetitive physical exercise may 
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improve the benefit of muscle contraction on breast cancer cytotoxicity. Our results 
clearly indicate that the benefit of exercise on cancer is derived from individual acute 
bouts of muscle contractions, and not impacted by chronic exercise per se. We did not 
observe a significant difference between the average percent reduction in cell 
proliferation between rats exposed to 5 weeks of exercise and normal cage ambulation.  
This study is the first to suggest that consistent/repetitive prior exercise does not improve 
the secretion of a chemotherapeutic factor from a single bout of exercise.  This actually 
goes against our original hypothesis that previous exercise conditioning would 
accentuate the cytotoxic effect of STM perfusate on breast cancer cells. Considering the 
elasticity of muscle and its ability to adapt by becoming more metabolically efficient 
(56), we assumed the same would hold true in the improvement in the release of a 
chemotherapeutic factor. This strongly suggests that this myokine is normally resident in 
the cell, and its manufacture is completely independent of physical conditioning. It also 
stands to reason that any individual expressing this myokine may benefit from physical 
activity, regardless of prior physical conditioning. Despite the additional effects on 
skeletal muscle metabolism from prior conditioning, our work highlights the advantages 
of each acute bout of exercise in the secretion of (a) chemotherapeutic factor(s). 
We should note that our capacity to fully understand the impact of a single bout 
of exercise or physical training on breast cancer is not possible with the current 
methodologies. Because our studies were not designed to assess dose-response per se, 
we chose to assess the impact of contracting muscle on cancer by exposing the cancer 
cells to what amounts to a continuous exercise session that spanned 24 hours each day 
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for 4 days (as they were harvested on day 5).  Since it is unlikely that individuals can 
endure those training behaviors, future studies should address dose-response 
relationships by allowing cells to be exposed to treatment media similar to what would 
be seen in vivo, by administering treatment media for briefer periods of time and 
followed by traditional cell media each day. That said, we must reemphasize our 
findings that perfusate arising from contracting skeletal muscle has a profound impact on 
breast cancer cell lines, which strongly provide a direct connection between physical 
activity and reduced cancer cell growth.  
 The acute exercise model of electrical stimulation via the nerve may be more 
physiologically correct than stimulation by other means, but this model is still not 
completely physiological. True neural activation in in vivo exercise activates the motor 
units in a synchronized fashion to match the forces required to meet the demand of the 
activity. Thus, not all motor units are fired for a given activity. Motor unit recruitment 
with electrical stimulation of skeletal muscle is an all or nothing response. In order to 
curb the impact of ‘all or nothing’ responses resulting from sciatic stimulation, we chose 
to only stimulate one limb, but perfuse both limbs to reduce the contribution of muscle 
mass in a reasonable manner. Given that only one limb was activated, it suggests that the 
myokine(s) involved with this process is (are) potent. Future studies may warrant the use 
of functional electrical stimulation that mimics locomotion during conditions of hind 
limb perfusion to determine if the incorporation of both limbs intensifies this response.  
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Albumin as a Required Carrier of the Chemotherapeutic Myokine(s) 
 Considering the many physiological functions of albumin in health (90), 
especially its role in drug-binding and delivery and its use in our methodologies, we 
assessed the role of albumin on the chemotherapeutic impact of contracting skeletal 
muscle. Our perfusion medium was designed to mimic the basics of plasma with 
physiological ratios of electrolytes and similar oncotic properties as well. The modified 
Krebs-Henseleit buffer solution we used contained 3.5% BSA, which is on the low end 
of human albumin plasma levels (35-50 mg mL-1) and the high end of rat albumin 
plasma concentrations (29 mg mL-1; (73)).  When we prepared our Krebs-Henseleit 
buffer for the HHLP without BSA and instead utilized Dextran as our oncotic agent, the 
chemotherapeutic effect of STM perfusate completely disappeared (Non-STM vs 
control, p = 0.402; STM vs control p = 0.813). These results perhaps emphasize 
albumin’s second most important role as a carrier molecule, in that whatever is secreted 
from contracting skeletal muscle capable of eliciting a chemotherapeutic effect on breast 
cancer cells requires albumin as a carrier through the vasculature. This notion differs 
from findings of Hoffman or Munoz (52, 82), where the chemotherapeutic effect of 
contracting muscle persisted even when BSA was not included in their in vitro saline 
bath preparation of electrically stimulated muscle, suggesting that albumin may be 
necessary to carry the factor through a vasculature (as in the present study), but not 
necessary when delivered to the cancer cell directly.  
In addition to the systemic role of albumin, it is also a major source of nitrogen 
and energy for extravascular cells, which is utilized after endocytosis and lysosomal 
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degradation. The plasma compartment is only estimated to contain about 42% of the 
total body albumin pool, with the rest abiding in extravascular compartments. This gives 
rise to the consideration that albumin is preferentially sequestered by tumor cells (127) 
to serve as a nutrient. Our perfusion medium may actually be providing the cells with an 
extra source of metabolic substrate to support their high metabolic activity, essentially 
potentiating their increase in cellular growth and proliferation. If so, this may allow for a 
glamorous entry of a potentially lethal factor if it indeed is being delivered by albumin to 
the cell.  
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CHAPTER V 
 SUMMARY AND CONCLUSIONS 
 
In summary, we provide evidence that the benefits of exercise on breast cancer, 
in part, can be attributed to the fundamental properties of contracting skeletal muscle, 
independent of humoral factors or altered physiological metabolism. Our hemicorpus 
hind limb perfusion model enabled us to collect substances secreted from skeletal 
muscle during quiescence and stimulated contraction, directly demonstrating the 
secretion of (a) chemotherapeutic factor(s) upon contraction. Our results demonstrated a 
profound 20% reduction of MCF7 breast cancer cells proliferation after 5 days of 
exposure to STM muscle perfusate. They also expand on previous studies and are the 
first to clearly implicate that the release of a chemotherapeutic factor is enhanced with 
the longer duration of muscle contractions, and that fatigue is not necessary to bring 
about its release. While one could reason that previous exercise conditioning may 
exaggerate these cytotoxic effects, the results of this study are also the first to offer the 
importance of muscle contractions as the mechanism of exercise that elicits cytotoxic 
benefits of exercise on breast cancer, arising from each acute bout rather than chronic 
exercise per se.  
Finally, our model highlights the physiological role of albumin as a potential 
carrier molecule of a variety of substances in mammalian plasma. Our results suggest the 
presence of albumin to be necessary to transport the chemotherapeutic myokine from 
contracting skeletal muscle through the vasculature.  
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